Medical cannabis treatment for chronic pain: Outcomes and prediction of response.
Journal
European journal of pain (London, England)
ISSN: 1532-2149
Titre abrégé: Eur J Pain
Pays: England
ID NLM: 9801774
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
24
01
2020
revised:
21
07
2020
accepted:
10
10
2020
pubmed:
17
10
2020
medline:
28
4
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
Although studied in a few randomized controlled trials, the efficacy of medical cannabis (MC) for chronic pain remains controversial. Using an alternative approach, this multicentre, questionnaire-based prospective cohort was aimed to assess the long-term effects of MC on chronic pain of various aetiologies and to identify predictors for MC treatment success. Patients with chronic pain, licensed to use MC in Israel, reported weekly average pain intensity (primary outcome) and related symptoms before and at 1, 3, 6, 9 and 12 months following MC treatment initiation. A general linear model was used to assess outcomes and identify predictors for treatment success (≥30% reduction in pain intensity). A total of 1,045 patients completed the baseline questionnaires and initiated MC treatment, and 551 completed the 12-month follow-up. At 1 year, average pain intensity declined from baseline by 20% [-1.97 points (95%CI = -2.13 to -1.81; p < 0.001)]. All other parameters improved by 10%-30% (p < 0.001). A significant decrease of 42% [reduction of 27 mg; (95%CI = -34.89 to 18.56, p < 0.001)] from baseline in morphine equivalent daily dosage of opioids was also observed. Reported adverse effects were common but mostly non-serious. Presence of normal to long sleep duration, lower body mass index and lower depression score predicted relatively higher treatment success, whereas presence of neuropathic pain predicted the opposite. This prospective study provides further evidence for the effects of MC on chronic pain and related symptoms, demonstrating an overall mild-to-modest long-term improvement of the tested measures and identifying possible predictors for treatment success.
Sections du résumé
BACKGROUND
Although studied in a few randomized controlled trials, the efficacy of medical cannabis (MC) for chronic pain remains controversial. Using an alternative approach, this multicentre, questionnaire-based prospective cohort was aimed to assess the long-term effects of MC on chronic pain of various aetiologies and to identify predictors for MC treatment success.
METHODS
Patients with chronic pain, licensed to use MC in Israel, reported weekly average pain intensity (primary outcome) and related symptoms before and at 1, 3, 6, 9 and 12 months following MC treatment initiation. A general linear model was used to assess outcomes and identify predictors for treatment success (≥30% reduction in pain intensity).
RESULTS
A total of 1,045 patients completed the baseline questionnaires and initiated MC treatment, and 551 completed the 12-month follow-up. At 1 year, average pain intensity declined from baseline by 20% [-1.97 points (95%CI = -2.13 to -1.81; p < 0.001)]. All other parameters improved by 10%-30% (p < 0.001). A significant decrease of 42% [reduction of 27 mg; (95%CI = -34.89 to 18.56, p < 0.001)] from baseline in morphine equivalent daily dosage of opioids was also observed. Reported adverse effects were common but mostly non-serious. Presence of normal to long sleep duration, lower body mass index and lower depression score predicted relatively higher treatment success, whereas presence of neuropathic pain predicted the opposite.
CONCLUSIONS
This prospective study provides further evidence for the effects of MC on chronic pain and related symptoms, demonstrating an overall mild-to-modest long-term improvement of the tested measures and identifying possible predictors for treatment success.
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-374Informations de copyright
© 2020 European Pain Federation - EFIC®.
Références
Abuhasira, R., Schleider, L.-B.-L., Mechoulam, R., & Novack, V. (2018). Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine, 49, 44-50. https://doi.org/10.1016/j.ejim.2018.01.019
Andreae, M. H., Carter, G. M., Shaparin, N., Suslov, K., Ellis, R. J., Ware, M. A., & Indyk, D. (2015). Inhaled cannabis for chronic neuropathic pain: An individual patient data meta-analysis. Journal of Pain, 6(12), 1221-1232. https://doi.org/10.1016/j.jpain.2015.07.009
Arnow, B. A., Hunkeler, E. M., Blasey, C. M., Lee, J., Constantino, M. J., Fireman, B., Kraemer, H. C., Dea, R., Robinson, R., & Hayward, C. (2006). Comorbid depression, chronic pain, and disability in primary care. Psychosomatic Medicine, 68(2), 262-268. https://doi.org/10.1097/01.psy.0000204851.15499.fc
Ashton, C. H. (2001). Pharmacology and effects of cannabis: A brief review. British Journal of Psychiatry, 178(2), 101-106. https://doi.org/10.1192/bjp.178.2.101
Aviram, J., & Samuelly-Leichtag, G. (2017). Efficacy of cannabis-based medicines for pain management: A systematic review and meta-analysis of randomized controlled trials. Pain Physician, 20(6), E755-E796.
Bates, D., Maechler, M., Bolker, B., & Walker, S. (2014). lme4: Linear mixed-effects models using Eigen and S4. R Package Version 1.7. Comprehensive R Archive Network (CRAN). Retrieved from CRANR-projectorg/package = lme4
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck Depression inventory-II. San Antonio, 78(2), 490-498.
Begg, C., Cho, M., Eastwood, S., Horton, R., Moher, D., Olkin, I., & Simel, D. (1996). Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA, 276(8), 637-639. https://doi.org/10.1001/jama.276.8.637
Bestard, J. A., & Toth, C. C. (2011). An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Practice, 11(4), 353-368. https://doi.org/10.1111/j.1533-2500.2010.00427.x
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013). The Pharmacologic and clinical effects of medical cannabis. Pharmacotherapy, 33(2), 195-209. https://doi.org/10.1002/phar.1187
Bradford, A. C., Bradford, W. D., Abraham, A., & Adams, G. B. (2018). Association between US state medical cannabis laws and opioid prescribing in the Medicare Part D population. JAMA Internal Medicine, 178(5), 667-672. https://doi.org/10.1001/jamainternmed.2018.0266
Brooks, R. & Group, E (1996). EuroQol: The current state of play. Health Policy, 37(1), 53-72. https://doi.org/10.1016/0168-8510(96)00822-6
Busse, J. W., Wang, L. I., Kamaleldin, M., Craigie, S., Riva, J. J., Montoya, L., Mulla, S. M., Lopes, L. C., Vogel, N., Chen, E., Kirmayr, K., De Oliveira, K., Olivieri, L., Kaushal, A., Chaparro, L. E., Oyberman, I., Agarwal, A., Couban, R., Tsoi, L., … Guyatt, G. H. (2018). Opioids for chronic noncancer pain: A systematic review and meta-analysis. Journal of American Medical Association, 320(23), 2448-2460. https://doi.org/10.1001/jama.2018.18472
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research, 28(2), 193-213. https://doi.org/10.1016/0165-1781(89)90047-4
Choo, E. K., Feldstein Ewing, S. W., & Lovejoy, T. I. (2016). Opioids out, cannabis in negotiating the unknowns in patient care for chronic pain. Journal of American Medical Association, 316(17), 1763-1764. doi: 10.1001/jama.2016.13677 [doi].
Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., & Atkinson, J. H. (2009). Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology, 34(3), 672-680. https://doi.org/10.1038/npp.2008.120
Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L., & Strom, B. L. (2000). Defining the clinically important difference in pain outcome measures. Pain, 88(3), 287-294. https://doi.org/10.1016/s0304-3959(00)00339-0
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G* Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39(2), 175-191. https://doi.org/10.3758/bf03193146
Feingold, D., Brill, S., Goor-Aryeh, I., Delayahu, Y., & Lev-Ran, S. (2017). Depression and anxiety among chronic pain patients receiving prescription opioids and medical marijuana. Journal of Affective Disorders, 218, 1-7. https://doi.org/10.1016/j.jad.2017.04.026
Ferguson, G., & Ware, M. A. (2015). Review Article: Sleep, Pain and Cannabis. Journal of Sleep Disorders & Therapy, 4(2), 191.
Fitzcharles, M. A., & Eisenberg, E. (2018). Medical cannabis: A forward vision for the clinician. European Journal of Pain, 22(3), 485-491. https://doi.org/10.1002/ejp.1185
Gewandter, J. S., McDermott, M. P., McKeown, A., Smith, S. M., Williams, M. R., Hunsinger, M., Farrar, J., Turk, D. C., & Dworkin, R. H. (2014). Reporting of missing data and methods used to accommodate them in recent analgesic clinical trials: ACTTION systematic review and recommendations. Pain, 155(9), 1871-1877. https://doi.org/10.1016/j.pain.2014.06.018
Haroutounian, S., Ratz, Y., Ginosar, Y., Furmanov, K., Saifi, F., Meidan, R., & Davidson, E. (2016). The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: a prospective open-label study. The Clinical Journal of Pain, 32(12), 1036-1043. https://doi.org/10.1097/AJP.0000000000000364
Hartman, R. L., & Huestis, M. A. (2013). Cannabis effects on driving skills. Clinical Chemistry, 59(3), 478-492. https://doi.org/10.1373/clinchem.2012.194381
Häuser, W., Finn, D. P., Kalso, E., Krcevski-Skvarc, N., Kress, H.-G., Morlion, B., Perrot, S., Schäfer, M., Wells, C., & Brill, S. (2018). European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. European Journal of Pain, 22(9), 1547-1564. https://doi.org/10.1002/ejp.1297
Hill, K. P., & Palastro, M. D. (2017). Medical cannabis for the treatment of chronic pain and other disorders: Misconceptions and facts. Polish Archives of Internal Medicine, 127(11), 785-789. https://doi.org/10.20452/pamw.4123
Hoggart, B., Ratcliffe, S., Ehler, E., Simpson, K. H., Hovorka, J., Lejčko, J., Taylor, L., Lauder, H., & Serpell, M. (2015). A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. Journal of Neurology, 262(1), 27-40. https://doi.org/10.1007/s00415-014-7502-9
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007). Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Current Medical Research and Opinion, 23(1), 17-24. https://doi.org/10.1185/030079906x158066
Kumar, R. N., Chambers, W. A., & Pertwee, R. G. (2008). Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia, 56(11), 1059-1068. https://doi.org/10.1111/j.1365-2044.2001.02269.x
Lahat, A., Lang, A., & Ben-Horin, S. (2012). Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: A pilot prospective study. Digestion, 85(1), 1-8. https://doi.org/10.1159/000332079
Landshaft, Y., Albo, B., Mechoulam, R., & Afek, A. (2017). The updated green book (May 2019): The official guide to clinical care in medical cannabis. Retrieved from https://www.health.gov.il/hozer/mmk154_2016.pdf. June 8, 2020
Lindsay, P. G., & Wyckoff, M.(1981). The depression-pain syndrome and its response to antidepressants. Psychosomatics, 22(7), 571-577. https://doi.org/10.1016/S0033-3182(81)73478-9
Little, R. J., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Neaton, J. D., Shih, W., Siegel, J. P., & Stern, H. (2012). The design and conduct of clinical trials to limit missing data. Statistics in Medicine, 31(28), 3433-3443. https://doi.org/10.1002/sim.5519
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., Neaton, J. D., Rotnitzky, A., Scharfstein, D., Shih, W. J., Siegel, J. P., & Stern, H. (2012). The prevention and treatment of missing data in clinical trials. New England Journal of Medicine, 367(14), 1355-1360. https://doi.org/10.1056/NEJMsr1203730
Martín-Sánchez, E., Furukawa, T. A., Taylor, J., & Martin, J. L. R. (2009). Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Medicine, 10(8), 1353-1368. https://doi.org/10.1111/j.1526-4637.2009.00703.x
Martin-Santos, R., Crippa, J. A., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M., Langohr, K., Farré, M., Zuardi, A. W., & McGuire, P. K.(2012). Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Current Pharmaceutical Design, 18(32), 4966-4979. https://doi.org/10.2174/138161212802884780
McCarty, D. (2018). Does medical cannabis reduce use of prescription opioids? American Journal of Psychiatry, 1(175), 6-7. https://doi.org/10.1176/appi.ajp.2017.17090958
Melzack, R. (1987). The short-form McGill pain questionnaire. Pain, 30(2), 191-197. https://doi.org/10.1016/0304-3959(87)91074-8
Meng, H., Johnston, B., Englesakis, M., Moulin, D. E., & Bhatia, A. (2017). Selective cannabinoids for chronic neuropathic pain: A Systematic Review and Meta-analysis. Anesthesia & Analgesia, 125(5), 1638-1652. https://doi.org/10.1213/ANE.0000000000002110
Michels, L., Moazami-Goudarzi, M., & Jeanmonod, D. (2011). Correlations between EEG and clinical outcome in chronic neuropathic pain: Surgical effects and treatment resistance. Brain Imaging and Behavior, 5(4), 329-348. https://doi.org/10.1007/s11682-011-9135-2
Moore, R. A., Moore, O. A., Derry, S., Peloso, P. M., Gammaitoni, A. R., & Wang, H. (2010). Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: Bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases, 69(2), 374-379. https://doi.org/10.1136/ard.2009.107805
Moore, T., Cohen, M., & Furberg, C. (2007). Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Archives of Internal Medicine, 167(16), 1752-1759. Retrieved from https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/486856.
Morean, M. E., & Lederman, I. R. (2019). Prevalence and correlates of medical cannabis patients’ use of cannabis for recreational purposes. Addictive Behaviors, 93, 233-239. https://doi.org/10.1016/j.addbeh.2019.02.003
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. The Cochrane Library, 7(3), https://doi.org/10.1002/14651858
Nugent, S. M., Morasco, B. J., O'Neil, M. E., Freeman, M., Low, A., Kondo, K., Elven, C., Zakher, B., Motu'apuaka, M., Paynter, R., & Kansagara, D. (2017). The effects of cannabis among adults with chronic pain and an overview of general harms: A systematic review. Annals of Internal Medicine, 167(5), 319-331. https://doi.org/10.7326/M17-0155
O’Connor, R. J., & Hurley, P. J. (2008). Existing technologies to reduce specific toxicant emissions in cigarette smoke. Tobacco Control, 17(1), 1-10. https://doi.org/10.1136/tc.2007.023689
Pollard, C. A. (1984). Preliminary validity study of the pain disability index. Perceptual and Motor Skills, 59(3), 974. https://doi.org/10.2466/pms.1984.59.3.974
Portenoy, R. K., Farrar, J. T., Backonja, M.-M., Cleeland, C. S., Yang, K., Friedman, M., Colucci, S. V., & Richards, P. (2007). Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study. The Clinical Journal of Pain, 23(4), 287-299. https://doi.org/10.1097/AJP.0b013e31802b582f
Qualtrics, L. L. C. (2015). Qualtrics (Version 1 2018). Provo, Utah, USA. Retrieved from http://www. qualtrics.com.
Roehrs, T., Zorick, F., Koshorek, G. L., Wittig, R., & Roth, T. (1983). Effects of acute administration of brotizolam in subjects with disturbed sleep. British Journal of Clinical Pharmacology, 16(Suppl 2), 371S-376S. https://doi.org/10.1111/j.1365-2125.1983.tb02312.x
Russo, E. B., Guy, G. W., & Robson, P. J. (2007). Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex®, a cannabis-based medicine. Chemistry & Biodiversity, 4(8), 1729-1743. https://doi.org/10.1002/cbdv.200790150
Shah, A., Craner, J., & Cunningham, J. L. (2017). Medical cannabis use among patients with chronic pain in an interdisciplinary pain rehabilitation program: Characterization and treatment outcomes. Journal of Substance Abuse Treatment, 77, 95-100. https://doi.org/10.1016/j.jsat.2017.03.012
Simpson, N. S., Scott-Sutherland, J., Gautam, S., Sethna, N., & Haack, M. (2018). Chronic exposure to insufficient sleep alters processes of pain habituation and sensitization. Pain, 159(1), 33-40. https://doi.org/10.1097/j.pain.0000000000001053
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092-1097. https://doi.org/10.1001/archinte.166.10.1092
Stith, S. S., Vigil, J. M., Adams, I. M., & Reeve, A. P. (2017). Effects of legal access to cannabis on scheduled II-V drug prescriptions. Journal of the American Medical Directors Association, 19(1), 59-64. https://doi.org/10.1016/j.jamda.2017.07.017
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018). Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: A systematic review and meta-analysis of controlled and observational studies. Pain, 159(10), 1932-1954. https://doi.org/10.1097/j.pain.0000000000001293
Sullivan, M. J. L., Bishop, S. R., & Pivik, J. (1995). The pain catastrophizing scale: Development and validation. Psychological Assessment, 7(4), 524. https://doi.org/10.1037/1040-3590.7.4.524
Sznitman, S. R., Vulfsons, S., Meiri, D., & Weinstein, G. (2020). Medical cannabis and insomnia in older adults with chronic pain: A cross-sectional study. BMJ Supportive & Palliative Care, 1-6, https://doi.org/10.1136/bmjspcare-2019-001938
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006). Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. Archives of General Psychiatry, 63(11), 1217-1223. https://doi.org/10.1001/archpsyc.63.11.1217
Ware, M. A., Wang, T., Shapiro, S., & Collet, J.-P. & Team, C. Study (2015). Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). Journal of Pain, 16(12), 1233-1242. https://doi.org/10.1016/j.jpain.2015.07.014
Wasan, A. D., Davar, G., & Jamison, R. (2005). The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain, 117(3), 450-461. https://doi.org/10.1016/j.pain.2005.08.006
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. Journal of American Medical Association, 313(24), 2456-2473. https://doi.org/10.1001/jama.2015.6358
Wickham, H. (2019). Tidyverse: Easily install and load ’Tidyverse" packages. Version 1.3.0. Comprehensive R Archive Network (CRAN). Retrieved from https://cran.r-project.org/web/packages/tidyverse/tidyverse.pdf
Wong, S. S. C., Chan, W. S., & Cheung, C. W. (2020). Analgesic effects of cannabinoids for chronic non-cancer pain: A systematic review and meta-analysis with meta-regression. Journal of Neuroimmune Pharmacology. https://doi.org/10.1007/s11481-020-09905-y
Yassin, M., Garti, A., & Robinson, D. (2016). Effect of medicinal cannabis therapy (MCT) on severity of chronic low back pain, sciatica and lumbar range of motion. International Journal of Anesthesiology & Pain Medicine, 2(5), 1-6. https://doi.org/10.21767/2471-982X.100014
Zaki, P., Blake, A., Wolt, A., Chan, S., Zhang, L., Wan, A., & O’HearnChan, S. (2017). The use of medical cannabis in common medical conditions excluding cancer. Journal of Pain Management, 10(4), 1-18.